Kamada Ltd. (KMDA) Rating Lowered to Hold at Zacks Investment Research
Kamada Ltd. (NASDAQ:KMDA) was downgraded by Zacks Investment Research from a “strong-buy” rating to a “hold” rating in a research note issued to investors on Wednesday.
According to Zacks, “Kamada Ltd. is a biopharmaceutical company. It develops, produces and markets therapeutics based on chromatographic purification technology. The company offers bio-therapeutics for specialty proteins, specific immunoglobulins and other prescription medicines. Kamada Ltd. is headquartered in Ness Ziona, Israel. “
A number of other research firms have also recently weighed in on KMDA. Jefferies Group reaffirmed a “buy” rating on shares of Kamada in a report on Friday, November 11th. TheStreet raised shares of Kamada from a “sell” rating to a “hold” rating in a report on Monday, September 26th.
Shares of Kamada (NASDAQ:KMDA) remained flat at $6.15 during mid-day trading on Wednesday. 2,221 shares of the stock traded hands. The company’s market capitalization is $223.97 million. Kamada has a one year low of $3.26 and a one year high of $6.29. The stock’s 50 day moving average price is $5.62 and its 200 day moving average price is $4.90.
ILLEGAL ACTIVITY NOTICE: “Kamada Ltd. (KMDA) Rating Lowered to Hold at Zacks Investment Research” was originally posted by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another website, it was illegally copied and reposted in violation of US and international trademark & copyright legislation. The correct version of this report can be accessed at http://www.dailypolitical.com/2017/01/13/kamada-ltd-kmda-rating-lowered-to-hold-at-zacks-investment-research.html.
A hedge fund recently raised its stake in Kamada stock. Vanguard Group Inc. increased its stake in shares of Kamada Ltd. (NASDAQ:KMDA) by 19.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 327,533 shares of the company’s stock after buying an additional 52,195 shares during the period. Vanguard Group Inc. owned 0.85% of Kamada worth $1,202,000 as of its most recent SEC filing. Institutional investors own 5.50% of the company’s stock.
Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kamada Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.